毒蕈碱受体激活剂作为精神分裂症新型治疗
尽管过去70年抗精神病药研发不断,精神分裂症治疗仍面临挑战,现有药物均作用于多巴胺D2受体,对阳性症状疗效有限且对阴性及认知症状相对无效。靶向毒蕈碱乙酰胆碱受体(mAChRs)的新型治疗已受关注超25年,近期临床试验证实了双M1/M4偏好性mAChR激动剂的抗精神病样及促认知作用。
要点
- 现有抗精神病药均作用于多巴胺D2受体,对阴性及认知症状相对无效。
- 靶向mAChRs的药物开发已关注超25年,近期临床试验证实其抗精神病样及促认知作用。
- 对呫诺美林(xanomeline)受体结合与激活特性的理解可指导未来mAChR靶向药物设计。
核心结论
- 靶向毒蕈碱乙酰胆碱受体的激活剂是精神分裂症新型治疗方向,近期临床试验证实了双M1/M4偏好性mAChR激动剂的抗精神病样及促认知作用。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- 过去70年开发的多种化学结构不同的抗精神病药安全性及耐受性改善,但疗效仅轻微差异。
- 所有当前获批的抗精神病药均作为多巴胺D2受体拮抗剂或部分激动剂。
- 除少数可能例外,抗精神病药对阳性症状疗效相似且中等,对阴性及认知症状相对无效。
- 超过25年前有报告称双M1/M4偏好性mAChR激动剂在阿尔茨海默病及精神分裂症个体中产生抗精神病样效应及促认知特性。
- 近期临床试验证实了上述发现,且对呫诺美林特定mAChRs结合与激活特性的理解进展可指导未来药物设计。
临床怎么用
- 提示临床关注靶向mAChRs的新型治疗策略,尤其是对阴性及认知症状的潜在益处。
局限性
- 本文为综述,未报告系统检索策略及纳入排除标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Achieving optimal treatment outcomes for individuals living with schizophrenia remains challenging, despite 70 years of drug development efforts. Many chemically distinct antipsychotics have been developed over the past 7 decades with improved safety and tolerability but with only slight variation in efficacy. All antipsychotics currently approved for the treatment of schizophrenia act as antagonists or partial agonists at the dopamine D2 receptor. With only a few possible exceptions, antipsychotic drugs have similar and modest efficacy for treating positive symptoms and are relatively ineffective in addressing the negative and cognitive symptoms of the disease. The development of novel treatments focused on targeting muscarinic acetylcholine receptors (mAChRs) has been of interest for more than 25 years following reports that treatment with a dual M1/M4-preferring mAChR agonist resulted in antipsychotic-like effects and procognitive properties in individuals living with Alzheimer's disease and schizophrenia; more recent clinical trials have confirmed these findings. In addition, advances in our understanding of the receptor binding and activation properties of xanomeline at specific mAChRs have the potential to inform future drug design targeting mAChRs.
引用
- Paul SM, Yohn SE, Brannan SK, et al. Muscarinic Receptor Activators as Novel Treatments for Schizophrenia. Biol Psychiatry. 2024. PMID: 38537670. doi:10.1016/j.biopsych.2024.03.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。